Registration Agenda 6-9 pm, Friday, April 8th Marriott City Center Salt Lake City, UT Exhibitor Registration Please contact Kristen Ray for more information. Kristen@mjexecmgmt.com PRESENTATIONS: The Government’s Experiment on Cancer Care (David C. Pittam, MHA, CMPE) Updates of ASCO’s Clinical Practice … Continued
The Leukemia & Lymphoma Society is pleased to share an online interactive education video simulation program titled, Navigating Treatment Failure in CML. This program enables you to explore aspects of CML management. Click Here for more information
On April 25, 2016, the U. S. Food and Drug Administration approved cabozantinib (CABOMETYX, Exelixis, Inc.) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.
The U. S. Food and Drug Administration approved venetoclax (VENCLEXTA tablets, marketed by AbbVie, Inc. and Genentech USA, Inc.) for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA-approved test, who have … Continued